{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:40:01Z","timestamp":1756359601154,"version":"3.44.0"},"reference-count":11,"publisher":"BMJ","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:p>The mucolytic drug \u25bcerdosteine (Erdotin \u2013 Galen) is licensed in the UK as treatment for up to 10 days \u201cfor the symptomatic treatment of acute exacerbations of chronic bronchitis in adults\u201d.1 This indication differs from that for carbocisteine and mecysteine, two older mucolytic drugs that are licensed for adjunctive treatment in respiratory disorders characterised by viscous mucus, and typically used for longer to prevent exacerbations of chronic obstructive pulmonary disease (COPD).2 Does erdosteine have a role for people with COPD exacerbations?<\/jats:p>","DOI":"10.1136\/dtb.2008.09.0024","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T17:52:35Z","timestamp":1222883555000},"page":"79-80","source":"Crossref","is-referenced-by-count":2,"title":["\u25bcErdosteine for copd exacerbations"],"prefix":"10.1136","volume":"46","member":"239","published-online":{"date-parts":[[2008,10,1]]},"reference":[{"key":"2025082722073667000_46.10.79.1","unstructured":"Erdotin 300 mg capsules Summary of product characteristics, UK. koGEN Limited: October 2006."},{"key":"2025082722073667000_46.10.79.2","first-page":"1","article-title":"National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care.","volume-title":"Thorax","volume":"59","author":"The National Collaborating Centre for Chronic Conditions","year":"2004"},{"key":"2025082722073667000_46.10.79.3","first-page":"344","article-title":"Effects of erdosteine and its metabolites on bacterial adhesiveness.","volume":"49","author":"Braga","year":"1999","journal-title":"Arzneim Forsch\/Drug Res"},{"key":"2025082722073667000_46.10.79.4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/dtb.2001.391181","volume":"39","author":"Managing stable chronic obstructive pulmonary disease","year":"2001","journal-title":"DTB"},{"key":"2025082722073667000_46.10.79.5","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2001.391181"},{"key":"2025082722073667000_46.10.79.6","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study.","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"},{"key":"2025082722073667000_46.10.79.7","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"key":"2025082722073667000_46.10.79.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66456-2"},{"key":"2025082722073667000_46.10.79.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200703-456SO"},{"key":"2025082722073667000_46.10.79.10","first-page":"35","article-title":"Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment.","volume":"4","author":"Mohanty","year":"2001","journal-title":"J Clin Research"},{"key":"2025082722073667000_46.10.79.11","first-page":"89","article-title":"Mucolytic activity of erdosteine double blind clinical trial vs placebo.","volume":"47","author":"Bisetti","year":"1995","journal-title":"Arch Med Interna"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2008.09.0024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:07:43Z","timestamp":1756357663000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2008.09.0024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2008,10,1]]},"published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1136\/dtb.2008.09.0024"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2008.09.0024","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}